Drug Trial Radar · NCT07156175
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Oct 14, 2025
Primary completion
Apr 8, 2027
Study completion May 6, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, placebo-controlled, multicenter, randomized, double-blind, Phase 2, proof of concept study. The study aims to evaluate the efficacy and safety of SAR444336 in adult participants with microscopic colitis. Participants are required to have a histologically confirmed diagnosis of microscopic colitis, be in clinical remission and be receiving budesonide therapy. The overall study duration is approximately 32 weeks.
Conditions
- Microscopic Colitis
Interventions
SAR444336Drug
Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
PlaceboDrug
Pharmaceutical form:Solution for injection -Route of administration:Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with sustained steroid-free clinical remissionTime frame: up to week 24
Locations
24 sites in 9 countries. Site status is shown where the registry gives one.
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 2080003
Aarhus, Denmark
Investigational Site Number : 2080002
Hvidovre, Denmark
Investigational Site Number : 2500001
Créteil, France
Investigational Site Number : 2500002
Montfermeil, France
Investigational Site Number : 2500003
Pessac, France
Investigational Site Number : 2760001
Frankfurt, Germany
Investigational Site Number : 2760005
Ludwigshafen, Germany
Investigational Site Number : 2760003
Tübingen, Germany
Investigational Site Number : 2760004
Ulm, Germany
Investigational Site Number : 3480002
Budapest, Hungary
Investigational Site Number : 3480003
Székesfehérvár, Hungary
Investigational Site Number : 3800004
Milan, Milano, Italy
Investigational Site Number : 3800001
Padua, Padova, Italy
Investigational Site Number : 3800003
Rome, Roma, Italy
Investigational Site Number : 3800002
Turin, Torino, Italy
Investigational Site Number : 6160004
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Investigational Site Number : 6160003
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160002
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 7520001
Linköping, Sweden
Investigational Site Number : 7520002
Stockholm, Sweden
Investigational Site Number : 7520003
Stockholm, Sweden
Investigational Site Number : 8260002
Cambridge, Cambridgeshire, United Kingdom
Investigational Site Number : 8260001
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.